Amazon to provide opioid overdose drug in workplace [Seeking Alpha]
Emergent BioSolutions Inc. (EBS)
Last emergent biosolutions inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: Seeking Alpha
“This initiative makes Amazon one of the first major companies to answer national authorities, non-profit leaders, and public health officials' calls on employers to stock the life-saving solution before an incident occurs,” Amazon said in a statement on its website “By confronting the public health emergency head-on, Amazon bolsters its emergency response procedures and sets an example for others to follow,” the company added. Naloxone is marketed under the brand name Narcan by Emergent BioSolutions ( NYSE: EBS ). A generic version of the drug is also sold by Teva ( NYSE: TEVA Amazon said it plans to stock the drug first in its most densely populated fulfillment centers. It expects to have the product in all of its U.S. operations sites by the early 2025. The company said the initiative is in line with guidance from the U.S. Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, the White House, and National Safety Council. Recom
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent BioSolutions Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Lyophilization Services for Biopharmaceuticals Industry Research Report 2024-2033: Drivers and Restraints, Competitive Landscape, Future Opportunities and Strategies [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions Inc. (NYSE: EBS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions Inc. (NYSE: EBS) had its price target raised by analysts at Benchmark Co. from $8.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
EBS
Earnings
- 11/6/24 - Beat
EBS
Sec Filings
- 11/21/24 - Form 3
- 11/14/24 - Form 4
- 11/13/24 - Form 4
- EBS's page on the SEC website